Recurrent hypermutant, MMR-deficient gliomas exhibit poor responses to ICB, likely due to the poor fitness and subclonal nature of therapy-induced neoantigens and a highly immunosuppressive tumor microenvironment with impaired antigen presentation13,66. This evidence concerns the gene MRC1 and glioma.